ARCHIVES

FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart

This article is from The Cancer Letter archive.

Vol. 36 No. 44 | December 3, 2010

Download PDF Visit The Full Archive

Related Articles

Memantine Can Delay Onset Of Cognitive Function Decline

November 30, 2012

Nader Group Backs FDA In controversy Over Drug Testing

February 11, 1977

NCI Contract Awards.

February 18, 2000

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014

“Sloppy Work” May Invalidate Methylene Chloride Study; Contractor Hints NTP Pressured By Industry

October 14, 1983

Phase II Study Of Pfizer Drug Meets Primary Endpoint

April 24, 2009